Dr. Judd Shellito

FACULTY

Judd Shellito

Credentialed MD;PROFESSOR - RESEARCH

Medicine - Emeritus Professors;Med-Pulmonary/Critical Care Me

Academic Office:

LSUHSC School of Medicine 
1901 Perdido Street
New Orleans, LA 70112

 

Bio

I have a longstanding interest in host defense of the lungs against infectious pathogens.  Currently I am involved in clinical research directed at how the gut microbiome directs inflammatory responses in the lung.  I oversee collection of samples for the LSUHSC COVID 19 Biorepository and am the lead LSUHSC site PI for the NIH-funded Recover Study of subjects with long COVID symptoms.  As Director of Clinical Research Resources for the Louisiana Clinical and Translational Research Center, I oversee clinical trials units throughout Louisiana.     

Education

Undergraduate:
1966-1970 - B.A.
Johns Hopkins University
Baltimore, Maryland

Medical:
1970-1974 - M.D.
Tulane University School of Medicine
New Orleans, Louisiana

Internship:
1974-1975 - Internal Medicine
Northwestern University School of Medicine
Evanston, Illinois

Residency:
1975 - 1977 - Internal Medicine
Northwestern University School of Medicine
Evanston, Illinois

Chief Residency:
1977 - 1978 - Internal Medicine
Northwestern University School of Medicine
Evanston, Illinois

Fellowship:
1978 - 1980 - Pulmonary
University of New Mexico School of Medicine
Albuquerque, New Mexico

Research Fellowship:
1980 - 1982 
Laboratory of H. Benfer Kaltredier, M.D.
University of California San Francisco, Cardiovascular Research Institute
San Francisco, California

Publications

1. Gu M, Samuelson DR, de la Rua NM, Charles TP, Taylor CM, Luo M, Siggins RW, Shellito JE, Welsh DA. Host innate and adaptive immunity shapes the gut microbiota biogeography. Microbiol Immunol. 2022 Jun;66(6):330-341.

2. Gu M, Samuelson DR, Taylor CM, Molina PE, Luo M, Siggins RW, Shellito JE, Welsh DA. Alcohol-associated intestinal dysbiosis alters mucosal-associated invariant T-cell phenotype and function. Alcohol Clin Exp Res. 2021 May;45(5):934-947.

3. Samuelson DR, Siggins RW, Ruan S, Amedee AM, Sun J, Zhu QK, Marasco WA, Taylor CM, Luo M, Welsh DA, Shellito JE. Alcohol consumption increases susceptibility to pneumococcal pneumonia in a humanized murine HIV model mediated by intestinal dysbiosis. Alcohol. 2019 Nov;80:33-43.

4. Samuelson DR, Burnham EL, Maffei VJ, Vandivier RW, Blanchard EE, Shellito JE, Luo M, Taylor CM, Welsh DA. The respiratory tract microbial biogeography in alcohol use disorder. Am J Physiol Lung Cell Mol Physiol. 2018 Jan 1;314(1):L107-L117.

5. Samuelson DR, Shellito JE, Maffei VJ, Tague ED, Campagna SR, Blanchard EE, Luo M, Taylor CM, Ronis MJJ, Molina PE, Welsh DA. Alcohol-associated intestinal dysbiosis impairs pulmonary host defense against Klebsiella pneumoniae. PLoS Pathog. 2017 Jun;13(6):e1006426.

6. Ruan S, Cai Y, Ramsay AJ, Welsh DA, Norris K, Shellito JE. B cell and antibody responses in mice induced by a putative cell surface peptidase of Pneumocystis murina protect against experimental infection. Vaccine. 2017 Jan 23;35(4):672-679.

7. Samuelson DR, Charles TP, de la Rua NM, Taylor CM, Blanchard EE, Luo M, Shellito JE, Welsh DA. Analysis of the intestinal microbial community and inferred functional capacities during the host response to Pneumocystis pneumonia. Exp Lung Res. 2016 Oct - Dec;42(8-10):425-439.

8. Dai G, Rady HF, Huang W, Shellito JE, Mason C, Ramsay AJ. Gene-based neonatal immune priming potentiates a mucosal adenoviral vaccine encoding mycobacterial Ag85B. Vaccine. 2016 Dec 7;34(50):6267-6275.

9. de la Rua NM, Samuelson DR, Charles TP, Welsh DA, Shellito JE. CD4(+) T-Cell-Independent Secondary Immune Responses to Pneumocystis Pneumonia. Front Immunol. 2016;7:178.

10. Lammi MR, Ghonim MA, Pyakurel K, Naura AS, Ibba SV, Davis CJ, Okpechi SC, Happel KI, deBoisblanc BP, Shellito J, Boulares AH. Treatment with intranasal iloprost reduces disease manifestations in a murine model of previously established COPD. Am J Physiol Lung Cell Mol Physiol. 2016 Apr 1;310(7):L630-8.
 
11. Charles TP, Shellito JE. Human Immunodeficiency Virus Infection and Host Defense in the Lungs. Semin Respir Crit Care Med. 2016 Apr;37(2):147-56.
 
12. Samuelson DR, de la Rua NM, Charles TP, Ruan S, Taylor CM, Blanchard EE, Luo M, Ramsay AJ, Shellito JE, Welsh DA. Oral Immunization of Mice with Live Pneumocystis murina Protects against Pneumocystis Pneumonia. J Immunol. 2016 Mar 15;196(6):2655-65.
 
13. Rady HF, Dai G, Huang W, Shellito JE, Ramsay AJ. Flagellin Encoded in Gene-Based Vector Vaccines Is a Route-Dependent Immune Adjuvant. PLoS One. 2016;11(2):e0148701.
 
14. Ruan S, Samuelson DR, Assouline B, Morre M, Shellito JE. Treatment with Interleukin-7 Restores Host Defense against Pneumocystis in CD4+ T-Lymphocyte-Depleted Mice. Infect Immun. 2016 Jan;84(1):108-19.
 
15. Samuelson DR, Welsh DA, Shellito JE. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015;6:1085.
 
16. Zheng M, Ramsay AJ, Robichaux MB, Kliment C, Crowe C, Rapaka RR, Steele C, McAllister F, Shellito JE, Marrero L, Schwarzenberger P, Zhong Q, Kolls JK. Corrigendum. CD4+ T cell-independent DNA vaccination against opportunistic infections. J Clin Invest. 2015 Mar 2;125(3):1364.
 
17. D'Souza AJ, Desai SD, Rudner XL, Kelly MN, Ruan S, Shellito JE. Suppression of the macrophage proteasome by ethanol impairs MHC class I antigen processing and presentation. PLoS One. 2013;8(2):e56890.
 
18. Kelly MN, Zheng M, Ruan S, Kolls J, D'Souza A, Shellito JE. Memory CD4+ T cells are required for optimal NK cell effector functions against the opportunistic fungal pathogen Pneumocystis murina. J Immunol. 2013 Jan 1;190(1):285-95.
 
19. Hernandez A, Gill FI, Aventura E, Mason C, Shellito J. Mediastinal pleomorphic sarcoma in an immunodeficient patient: case report and review of the literature. J La State Med Soc. 2012 Jan-Feb;164(1):21-5.
 
20. Zheng M, Rapaka RR, Yu AC, Shellito JE, Kolls JK. Role of interleukin-23-dependent antifungal immune responses in dendritic cell-vaccinated mice. Infect Immun. 2011 Sep;79(9):3778-83.
 

Research

Active Grants

Title: Alcohol-induced Dysbiosis and HIV-associated Pneumonia
Sponsor: R21 AA027199 NIH / NIAAA Welsh
Role: Principal Investigator
Dates: 09/24/19 – 08/31/21
Details: This project will uncover mechanisms through which changes in gut microflora influence host responses to pulmonary infection (the gut-lung axis) and add new knowledge as to how alcohol and HIV infection impair immunity in the lung.

Title: Institutional Development Award (IDeA) for Louisiana Clinical and Translational Research
Sponsor: National Center for Research Resources (NIH)
Role: Co-Key Component Leader, Clinical Research Resources and Facilities (J Kirwan, PI) 
Dates: 7/1/17-6/30/22
Details: This CTSA type grant provides comprehensive infrastructure support for clinical/translational research for LSUHSC, Tulane Health Sciences Center, and Pennington Biomedical Research Center.  The Clinical Research Resources component will establish clinical research offices at each institution and provide young investigators access to clinical trials support as well as other components of the overall award.
Total Award Amount: $20,000,000

Title: Nutrition for Precision Health
Sponsor: National Institute of Diabetes and Kidney Disease
Dates: 12/10/21-11/30/26
Details: This study is linked to the All-of-Us genomics study and will investigate dietary interventions as they impact a variety of health measures and outcomes.  Subjects will be enrolled and studied at LSUHSC in New Orleans as well as at Pennington Biomedical in Baton Rouge and NIDDK in Phoenix.  For Module 1 LSUHSC will enroll and study 600 participants.  For Module 2, LSUHSC will enroll and retain 100 participants for dietary interventions.
Total Award Amount: $8,562,202

Title: IDEA States Consortium for Clinical Research (ISCORE) Network
Sponsor: National Heart Lung and Blood Institute
Dates: 12/1/21 – 11/30/26
Details: This is a long COVID study with multiple sites across the US.  LSUHSC is part of a hub site including Tulane and Pennington Biomedical Research Institute.  Subjects who have recovered from COVID will be enrolled in the study and will be followed and tested quarterly for four years.
Total Award Amount: $1,495,699